Life Sciences
India’s pharmaceutical sector, a critical player in the global healthcare ecosystem, provides over 60% of the world’s demand for various vaccines, 40% of generic demand in the US, and 25% of all medicines in the UK.
The sector is expected to grow significantly, propelled by a strong generic drugs market, substantial exports, and a skilled workforce. With the Indian government setting a vision to position the country as a global hub for end-to-end drug discovery, the sector’s growth is supported by multiple funds.
For foreign pharmaceutical companies, the Indian market offers vast opportunities amidst challenges such as navigating regulatory environments, understanding market dynamics, and leveraging government schemes. StraTiger’s expertise in the Indian pharmaceutical landscape empowers foreign entities to seize these opportunities:
- Market Entry and Expansion
- Regulatory Navigation
- Investment Advisory
- Government Schemes and Initiatives
- Generic Drug Market
- Chronic Disease Market
StraTiger’s comprehensive support framework ensures that foreign pharmaceutical companies can navigate the complexities of the Indian market, from regulatory compliance and market entry strategies to capitalizing on growth opportunities and aligning with government initiatives, thereby achieving sustainable success in one of the world’s most vibrant pharmaceutical markets.